Immuron might have the market to themselves. From page 2 of...

Immuron might have the market to themselves.

From page 2 of IMC's latest Annual Report:

Immuron now has one of the most compelling portfolios of fatty liver trials in the industry. We have been working towards this goal in FY2016 and we are encouraged by the three shots on goal we are providing to our investors and potential partners.

It is now increasingly recognised that NASH is a multi-factorial disease that needs to be targeted from a range of MOAs (Mechanism of Action) not simply by targeting one MOA. NASH KOLs feel that is the reason why our major competitors have shown lacklustre results to date and why we are uniquely positioned for long-term success.

Unlike our competitors, IMM-124E targets the disease upstream allowing a much broader impact on lowering systemic and liver inflammation. In combination with our unique safety profile this should allow IMM-124E the ability to 1) Be used on a long-term chronic basis and 2) Target a broader NASH patient population including late NASH patients as well as early stage patients. This is truly unique among all of our current competitors.

The Phase II results of two competitors, Genfit SA and Tobira Therapeutics were mentioned and neither trial met their primary endpoints.